Incidence and risk factors for osteoporotic fractures in patients with systemic lupus erythematosus versus matched controls.

BACKGROUND/AIMS: Despite recent improvements in the quality of life of patients with systemic lupus erythematosus (SLE), osteoporosis, and osteoporotic fractures are one of the major complications of SLE. Furthermore, limited data are available on the incidence and predictor of osteoporotic fractures in Korean patients with SLE. Herein, we aimed to assess the incidence and risk factors for osteoporotic fractures in Korean SLE patients compared to those without SLE.
METHODS: SLE patients aged ≥ 40 years (n = 10,434; mean age, 51.3 ± 9.1 years; women, 89.7%) were selected from the Korean National Health Insurance Service database, spanning a period from 2008 to 2014. Age- and sex-matched controls (n = 52,170) were randomly sampled in a 5:1 ratio from non-SLE individuals. The primary outcome was the first occurrence of osteoporotic fracture.
RESULTS: The incidence of osteoporotic fractures was significantly higher in the SLE patients (19.085 per 1,000 person-years) than in matched controls (6.530 per 1,000 person-years). According to the multivariable Cox proportional analysis, patients with SLE exhibited a higher osteoporotic fracture rate than the control group (hazards ratio, 2.964; 95% confidence interval, 2.754 to 3.188), even after adjustment for confounding variables. In the subgroup analysis, male SLE patients or SLE patients aged 40 to 65 years were associated with a higher osteoporotic fracture rate than women SLE patients or SLE patients aged ≥ 65 years, respectively.
CONCLUSION: We found a 2.964-fold increased risk of osteoporotic fracture in SLE patients compared to age- and sex-matched non-SLE controls. Male or middle-aged SLE patients had a relatively higher fracture risk among patients with SLE.

INTRODUCTION

The prevalence of osteoporosis and osteoporotic fractures, which are common metabolic conditions associated with aging, is dramatically increasing due to rapidly aging populations in most developing and developed countries. Since osteoporotic fractures not only reduce quality-of-life but also increase medical and health care expenses, this condition imposes a significant healthcare and financial burden [1,2].

Systemic lupus erythematosus (SLE) is predominant among African Americans, Native Americans, Hispanics, and Asians, and both the prevalence and incidence of SLE are increasing in the Korean population [3]. In Korea, the prevalence and incidence of SLE between 2006 and 2010 was 20.6 to 26.5 (per 100,000 person) and over 2.5 (per 100,000 person), respectively [4]. SLE is a chronic systemic autoimmune disorder that commonly affects bone homeostasis, which is associated with increased serum levels of various inflammatory cytokines, premature menopause, and maintaining glucocorticoids therapy [5-11]. Recently, a population-based study showed that the incidence ratios for cervical hip fractures in SLE patients were about 3-time higher than those in age- and sex-matched healthy subjects [8]. Moreover, the incidence of fragility fractures in SLE patients increases in younger-aged patients compared to the general population [6,12]. However, limited data are available on the incidence, as well as the risk factors, of osteoporotic fractures in Korean patients with SLE.

The aim of the present study was to determine the incidence rate (IR) of osteoporotic fractures between SLE patients and age- and sex-matched controls, as well as to determine the risk factors for osteoporotic fractures among SLE patients, using nationwide population-based data in Korea.

METHODS

Data source and study population

We used the national health insurance claims database established by the National Health Insurance Service (NHIS) of Korea [13]. This database includes all claims data provided by the NHIS program and the Medical Aid program. The Korean NHIS program is a compulsory social insurance scheme that covers approximately 97% of the Korean population; the remaining 3% are protected under the Medical Aid program [14]. Information on Medical Aid beneficiaries has been integrated into the NHIS database since 2006. Therefore, data extracted from the NHIS database are considered to represent the entire Korean population. The authors obtained approval from the Institutional Review Board of Chonnam National University Hospital, South Korea (CNUH-EXP-2018-026). Informed consent was waived by the Institutional Review Board.

In this study, age, sex, and diagnostic codes based on the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) were retrieved. Patients were categorized as part of the SLE group if they had been treated under M32 of the ICD-10-CM code at least five times between 2008 and 2014; this definition was used previously [15].

Of the 49,884,461 people who underwent at least one health examination between 2008 and 2014, those with a history of fracture during a washout period from 2005 to 2007 to reduce confounding of previous diagnosed fracture or those aged < 40 years were excluded because osteoporotic fracture is rare in this subpopulation. A total of 10,434 patients with SLE was included in the present study (Supplementary Fig. 1). The subjects comprising the control group were randomly selected from an initial screening of all patients who had undergone an appendectomy or hemorrhoid surgery without a diagnosis of SLE during the same period, such that there were five age- and sex-matched controls per SLE patient.

Definition

Diabetes was identified based on diagnostic codes (E10–14) from the ICD-10-CM for a self-reported medical history of diabetes or a fasting serum glucose level ≥ 126 mg/dL in the health examination database. Hypertension was defined as previous hypertension diagnosis (I10–13, I15), history of taking at least one antihypertensive drug, or having a blood pressure ≥ 140/90 mmHg in the health examination database. Dyslipidemia was identified by the diagnostic code E78, self-reported use of lipid-lowering drugs, or a total cholesterol level ≥ 240 mg/dL in the health examination database. Lower income level was defined at the lowest 20%. Cancer information was collected according to the cancer codes (C00–96). Stroke and ischemic heart disease were defined by the diagnostic codes I63–64, and I20–25, respectively. Congestive heart failure was defined by the diagnostic code I50, and chronic obstructive pulmonary disease (COPD) was identified based on diagnostic codes (J41–J44). End-stage renal disease (ESRD) was defined using the diagnostic codes N18–19 and special medical aid codes for renal replacement therapy (V001, V003, V005). Osteoporotic fracture was defined by diagnostic codes M80 (osteoporosis with pathological fracture), with M81 (osteoporosis without pathological fracture) or M82 (osteoporosis in disease classified as others) being used for 5 years before these other fracture codes (S22.0, S22.1, S32.0, M48.4, M48.5, S72.0, S72.1, S42.0, S42.2, S42.3, S52.5, S52.6, S82.3, S82.5, and S82.6) [16].

Subgroup analysis

Subgroup analysis were performed to assess the effect on the risk of osteoporotic fracture in SLE patients, compared with non-SLE individuals, according to sex; age (40 to 64 and > 65 years); degree of income; previous history of either diabetes, hypertension, or dyslipidemia; cancer; COPD; ischemic heart disease; stroke; congestive heart failure, and ESRD.

Statistical analyses

Prevalence was calculated as the number of cases divided by the total population in 2014. Data were presented as proportions for continuous or categorical variables or mean ± standard deviation. Multivariable Cox regression analysis was conducted to determine hazard ratio (HR) and the 95% confidence interval (CI) for associations between SLE and osteoporotic fracture. Calculations were adjusted for age; sex; lower income; and a previous history of either diabetes, hypertension, or dyslipidemia. The incidence probability of osteoporotic fracture according to the presence of SLE was calculated using the Kaplan-Meier method, and the log-rank test was used to analyze differences between study groups. The associations of SLE with osteoporotic fracture were examined in relevant subgroups of patients. Potential interactions were formally tested by including interaction terms. All statistical tests were two-tailed, and p < 0.05 was considered significant. All data analyses were carried out using SAS software version 9.4 (SAS Institute, Cary, NC, USA).

RESULTS

Characteristics of the study population

We identified and evaluated the records of 10,434 patients with SLE who were aged at least 40 years as well as 52,170 age- and sex-matched control subjects without SLE for the data analysis. The characteristics of the SLE patients and the age- and sex-matched controls are shown in Table 1. The mean age of the SLE patients and the control group was 51.27 ± 9.07 years; those aged over 65 years and women comprised 10.2% and 89.7% of the study cohorts, respectively. SLE patients had a significantly higher prevalence of hypertension, diabetes, dyslipidemia, cancer, COPD, ESRD, ischemic heart disease, stroke, and congestive heart failure. There was no difference in income level between both groups.

Table 1.

Baseline characteristics of the SLE patients and the age- and sex-matched controls

Characteristic	SLE		p value
	No (n = 52,170)	Yes (n = 10,434)
Female sex	46,800 (89.71)	9,360 (89.71)	1.000
Age, yr	51.27 ± 9.07	51.27 ± 9.07	1.000
≥ 65 yr	5,305 (10.17)	1,061 (10.17)	1.000
Low income	13,243 (25.38)	2,706 (25.93)	0.239
Diabetes mellitus	3,135 (6.01)	728 (6.98)	0.001
Hypertension	9,090 (17.42)	3,382 (32.41)	< 0.001
Dyslipidemia	5,404 (10.36)	1,754 (16.81)	< 0.001
Cancer	1,493 (2.86)	443 (4.25)	< 0.001
COPD	6,490 (12.44)	2,622 (25.13)	< 0.001
ESRD	90 (0.17)	229 (2.19)	< 0.001
Ischemic heart disease	4,087 (7.83)	2,174 (20.84)	< 0.001
Stroke	1,466 (2.81)	730 (7)	< 0.001
Congestive heart failure	734 (1.41)	510 (4.89)	< 0.001
Osteoporotic fracture	2,036 (3.9)	1,139 (10.92)	< 0.001
Follow-up duration, yr	5.98 ± 2.3	5.72 ± 2.43	< 0.001
Age at osteoporotic facture occurrence, yr	63.86 ± 8.95	60.32 ± 9.44	< 0.001
Frequency of osteoporotic fracture by age group, yr			< 0.001
40−44	11 (0.54)	37 (3.25)
45−49	65 (3.19)	95 (8.34)
50−54	253 (12.43)	221 (19.4)
55−59	383 (18.81)	225 (19.75)
60−64	359 (17.63)	188 (16.51)
65−69	385 (18.91)	165 (14.49)
70−74	321 (15.77)	112 (9.83)
≥ 75	259 (12.72)	96 (8.43)

Values are presented as number (%) or mean ± SD.

SLE, systemic lupus erythematosus; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease.

Increased osteoporotic fracture in SLE patients and matched controls

The follow-up duration was shorter in SLE patients than in controls (5.72 ± 2.43 years vs. 5.98 ± 2.30 years, p < 0.001). During a follow-up period, osteoporotic fracture developed more frequently in 1,139 SLE patients (10.9%) than in 2,036 matched controls (3.9%) (p < 0.001). Among the patients with osteoporotic fractures, the frequency of osteoporotic fractures was higher in SLE patients than in matched controls before menopause (Table 1). During 59,680 person-years of follow-up, the IR for osteoporotic fracture was 19.085 cases per 1,000 person-years in SLE patients, while IR was 6.530 cases per 1,000 person-years in the control group. SLE patients were independently associated with osteoporotic fracture, even after adjustment for clinical variables (HR, 2.964; 95% CI, 2.754 to 3.188) (Table 2). Kaplan-Meier curves for the crude 8-year incidence probability of osteoporotic fracture in SLE patients and the control group is shown in Fig. 1. Patients with SLE had significantly higher osteoporotic fracture incidence than non-SLE-matched controls, regardless of gender.

Table 2.

Association between SLE and osteoporotic fracture

SLE	Number	OF	Follow-up duration, person-yr	IR[a]	Model 1[b]	Model 2[c]	Model 3[d]
No	52,170	2,036	311,796.75	6.530	1 (ref)	1 (ref)	1 (ref)
Yes	10,434	1,139	59,680.29	19.085	2.927 (2.722–3.146)	3.02 (2.808–3.246)	2.964 (2.754–3.188)

Values are presented as hazard ratio (95% confidence interval).

SLE, systemic lupus erythematosus; OF, osteoporotic fracture; IR, incidence rate.

IR per 1,000 person-years.

No adjusted.

Adjusted for age and sex.

Adjusted for age, sex, lower income, and previous history of diabetes, hypertension, and dyslipidemia.

Figure 1.

Kaplan-Meier curves for the crude cumulative 8-year osteoporotic fracture between systemic lupus erythematosus (SLE) and non-SLE patients in (A) total, (B) male, and (C) female (p of log-rank < 0.001).

In the subgroup analysis, the pattern of association between SLE and IR for osteoporotic fracture was qualitatively similar across subgroups. Male SLE patients had a higher osteoporotic fracture risk than female SLE patients, even after adjustment for confounding variables ([HR, 4.706; 95% CI, 3.358 to 6.582] vs. [HR, 2.899; 95% CI, 2.688 to 3.124], p for interaction = 0.004). Moreover, SLE patients aged between 40 and 65 years had a higher relative risk of osteoporotic fracture than those aged ≥ 65 years ([HR, 3.383; 95% CI, 3.102 to 3.687] vs. [HR, 2.223; 95% CI, 1.927 to 2.556], p for interaction < 0.001). SLE patients without a history of cancer, ischemic heart disease, or stroke also had a higher relative risk of osteoporotic fracture than those with a previous history of cancer, ischemic heart disease, or stroke. However, no significant difference was found among SLE patients with respective to income level or a previous history of diabetes, hypertension, dyslipidemia, COPD, ESRD, or congestive heart failure (Table 3, Fig. 2).

Table 3.

Subgroup analysis according to various baseline characteristics between SLE and osteoporotic fracture

Variable	SLE	Number	OF	Follow-up duration, person-year	IR[a]	Model 1[b]	Model 2[c]	Model 3[d]	p for interaction
Sex
Male	No	5,370	73	30,065.8	2.43	1 (ref)	1 (ref)	1 (ref)	0.004
	Yes	1,074	67	5,830.6	11.49	4.718 (3.381–6.573)	4.821 (3.455–6.717)	4.706 (3.358–6.582)
Female	No	46,800	1,963	281,730.9	6.97	1 (ref)	1 (ref)	1 (ref)
	Yes	9,360	1,072	53,849.7	19.91	2.862 (2.656–3.082)	2.952 (2.739–3.179)	2.899 (2.688–3.124)
Age groups
40−64	No	46,865	1,350	285,950.1	4.72	1 (ref)	1 (ref)	1 (ref)	< 0.001
	Yes	9,373	866	55,045.5	15.73	3.345 (3.071–3.642)	3.441 (3.158–3.746)	3.383 (3.102–3.687)
≥ 65	No	5,305	686	25,846.7	26.54	1 (ref)	1 (ref)	1 (ref)
	Yes	1,061	273	4,634.8	58.90	2.21 (1.918–2.539)	2.219 (1.926–2.55)	2.223 (1.927–2.556)
Income
Other	No	38,927	1,494	232,817.6	6.42	1 (ref)	1 (ref)	1 (ref)	0.388
	Yes	7,728	833	44,826.6	18.58	2.898 (2.662–3.154)	2.979 (2.736–3.242)	2.925 (2.684–3.186)
Low 20%	No	13,243	542	78,979.1	6.86	1 (ref)	1 (ref)	1 (ref)
	Yes	2,706	306	14,853.7	20.60	3.013 (2.616–3.463)	3.18 (2.761–3.656)	3.109 (2.697–3.578)
Diabetes
No	No	49,035	1,773	294,821.8	6.01	1 (ref)	1 (ref)	1 (ref)	0.069
	Yes	9,706	1,026	55,934.9	18.34	3.055 (2.828–3.299)	3.108 (2.877–3.355)	3.015 (2.789–3.258)
Yes	No	3,135	263	16,975.0	15.49	1 (ref)	1 (ref)	1 (ref)
	Yes	728	113	3,745.4	30.17	1.948 (1.557–2.421)	2.353 (1.879–2.928)	2.37 (1.892–2.951)
Hypertension
No	No	43,080	1,387	260,623.8	5.32	1 (ref)	1 (ref)	1 (ref)	0.920
	Yes	7,052	637	40,781.8	15.62	2.947 (2.682–3.235)	2.977 (2.709–3.269)	2.961 (2.694–3.251)
Yes	No	9,090	649	51,173.0	12.68	1 (ref)	1 (ref)	1 (ref)
	Yes	3,382	502	18,898.5	26.56	2.096 (1.864–2.353)	2.783 (2.472–3.131)	2.794 (2.481–3.145)
Dyslipidemia
No	No	46,766	1,663	283,494.0	5.87	1 (ref)	1 (ref)	1 (ref)	0.753
	Yes	8,680	898	50,413.8	17.81	3.043 (2.805–3.3)	3.027 (2.79–3.282)	2.978 (2.743–3.232)
Yes	No	5,404	373	28,302.8	13.18	1 (ref)	1 (ref)	1 (ref)
	Yes	1,754	241	9,266.5	26.01	1.976 (1.679–2.322)	2.723 (2.306–3.209)	2.729 (2.309–3.219)
Cancer
No	No	50,677	1,942	303,561.3	6.40	1 (ref)	1 (ref)	1 (ref)	0.004
	Yes	9,991	1,088	57,337.7	18.98	2.971 (2.758–3.199)	3.086 (2.865–3.323)	3.024 (2.805–3.259)
Yes	No	1,493	94	8,235.4	11.41	1 (ref)	1 (ref)	1 (ref)
	Yes	443	51	2,342.6	21.77	1.902 (1.344–2.662)	1.852 (1.307–2.594)	1.864 (1.311–2.62)
COPD
No	No	45,680	1,567	274,033.5	5.72	1 (ref)	1 (ref)	1 (ref)	0.197
	Yes	7,812	724	45,216.2	16.01	2.807 (2.568–3.063)	2.974 (2.722–3.247)	2.923 (2.673–3.193)
Yes	No	6,490	469	37,763.2	12.42	1 (ref)	1 (ref)	1 (ref)
	Yes	2,622	415	14,464.1	28.69	2.31 (2.024–2.636)	2.601 (2.278–2.969)	2.596 (2.272–2.965)
ESRD
No	No	52,080	2,028	311,306.4	6.51	1 (ref)	1 (ref)	1 (ref)	0.141
	Yes	10,205	1,114	58,479.1	19.05	2.928 (2.721–3.15)	3.021 (2.808–3.25)	2.973 (2.761–3.2)
Yes	No	90	8	490.3	16.32	1 (ref)	1 (ref)	1 (ref)
	Yes	229	25	1,201.2	20.81	1.252 (0.59–2.967)	1.461 (0.684–3.48)	1.344 (0.618–3.249)
Ischemic heart disease
No	No	48,083	1,679	288,487.1	5.82	1 (ref)	1 (ref)	1 (ref)	0.007
	Yes	8,260	805	47,699.1	16.88	2.907 (2.672–3.161)	3.126 (2.873–3.399)	3.078 (2.826–3.351)
Yes	No	4,087	357	23,309.7	15.32	1 (ref)	1 (ref)	1 (ref)
	Yes	2,174	334	11,981.2	27.88	1.82 (1.567–2.112)	2.236 (1.923–2.598)	2.243 (1.927–2.609)
Stroke
No	No	50,704	1,880	303,717.6	6.19	1 (ref)	1 (ref)	1 (ref)	0.043
	Yes	9,704	1,028	55,678.3	18.46	2.988 (2.768–3.223)	3.086 (2.859–3.329)	3.026 (2.802–3.267)
Yes	No	1,466	156	8,079.1	19.31	1 (ref)	1 (ref)	1 (ref)
	Yes	730	111	4,002.0	27.74	1.439 (1.126–1.832)	1.956 (1.52–2.51)	2.001 (1.55–2.576)
Congestive heart failure
No	No	51,436	1,963	307,995.9	6.37	1 (ref)	1 (ref)	1 (ref)	0.249
	Yes	9,924	1,061	57,201.7	18.55	2.915 (2.704–3.14)	3.038 (2.819–3.273)	2.994 (2.776–3.228)
Yes	No	734	73	3,800.8	19.21	1 (ref)	1 (ref)	1 (ref)
	Yes	510	78	2,478.6	31.47	1.623 (1.179–2.236)	2.115 (1.524–2.938)	2.114 (1.522–2.94)

Values are presented as hazard ratio (95% confidence interval).

SLE, systemic lupus erythematosus; OF, osteoporotic fracture; IR, incidence rate; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease.

IR per 1,000 person-years.

No adjusted.

Adjusted for age and sex.

Adjusted for age, sex, lower income, and previous history of diabetes, hypertension, and dyslipidemia.

Figure 2.

Overall and subgroup analysis of association between systemic lupus erythematosus (SLE) and osteoporotic fracture in adjusted model. Points and bars represent hazard ratio estimate and 95% confidence interval, respectively. COPD, chronic obstructive pulmonary disease; ESRD, endstage renal disease; IHD, ischemic heart disease; CHF, congestive heart failure.

DISCUSSION

In this study that analyzed nationwide, population-based data, we found that patients with SLE may have a higher osteoporotic fracture risk than age- and sex-matched control cohorts. There was no significant difference in the osteoporotic fracture risk of SLE patients, with regard to either having a low income level, or a previous history of diabetes, hypertension, dyslipidemia, COPD, ESRD, or congestive heart failure, compared to SLE patients without such characteristics. However, male or younger-aged SLE patients as well as those not having a previous history of either ischemic heart disease, stroke, or cancer showed a higher relative osteoporotic fracture risk among SLE patients.

Although SLE patients have been shown to be at a higher risk of symptomatic vertebral fracture in several small cross-sectional studies [17-20], the association between osteoporotic fracture and SLE in a population-based cohort has not been well characterized. An early retrospective cohort study of 702 female SLE patients found a nearly 5-fold increase in fracture incidence compared with the general United States female population [7]. In a recent large population-based study from Taiwan, there was an approximately 3.2-fold higher incidence of cervical hip fractures in 14,544 SLE patients than in age- and sex-matched controls, and that fracture risk was elevated starting at a younger age than the general population [8]. Another population-based study in the United Kingdom analyzed a total of 4,343 SLE patients, as well as 21,780 age- and sex-matched controls. This study showed a 1.2-fold increase in the risk of clinical fracture for SLE patients, when compared to controls, using a mean follow-up period of 6.4 years [10]. In line with previous studies, after adjustment for confounding variables, our results showed that SLE patients had a 2.96-fold increase in the risk of osteoporotic fracture, when compared to age- and sex-matched non-SLE controls, which was similar to above study from Taiwan. The reason for the differences in relative risk of fracture between previous population-based studies may be due to racial disparities and disease severities between the different study populations.

Mechanistically, SLE is a chronic inflammatory state that contributes to bone loss by increasing osteoclast activity, while reducing activity of osteoblasts [21]. This appeared to be mediated by the elevated expression of receptor activator of nuclear factor-κB ligand (RANKL), tumor necrosis factor, and interleukin-1 and -6 [5,22]. Of note, increased oxidized low-density lipoprotein correlated negatively with low bone-mineral density of the lumbar spine and total hip in SLE patients, which may attenuate osteoblast maturation and increase the expression of RANKL, which may eventually induce osteoporosis [23]. Moreover, SLE patients may have lower vitamin D levels as a result of the avoidance of sun exposure, decreased renal function, and the use of glucocorticoids, anticonvulsants, hydroxychloroquine, and calcineurin inhibitors. Low levels of vitamin D is also associated with disease severity via inappropriate immune response and has been shown to be correlated with osteoporosis in SLE patients [21,24].

Notwithstanding the fact that men comprised 10% of the study cohort, which is similar to previous SLE cohort studies [8,10,25], our results identified male SLE patients have a high risk of osteoporotic fracture in the SLE cohort according to subgroup analysis. Similar to our findings, a study from United Kingdom showed a higher relative risk of clinical fracture in male SLE patients than in female SLE patients (adjusted relative risk, 1.91 vs. 1.18), although statistical significance was not found [10]. Furthermore, SLE patients aged 40 to 65 years were at an increased relative risk of osteoporotic fracture when compared to SLE patients older than 65 years. This finding was consistent with a previous study from Taiwan that found the incidence of hip fracture was higher in SLE patients younger than 50 years than in those aged ≥ 50 years [8]. Although the IR of osteoporotic fracture increases with age among the SLE cohort (aged 40 to 65 years, 7.4 cases per 1,000 person-years; aged ≥ 65 years, 32.6 cases per 1,000 person-years), the relative risk was higher for younger SLE patients than for older SLE patients when compared with matched controls. In other words, despite the incidence of osteoporotic fracture is low in male and young general population, male or younger SLE patients had a relatively higher fracture risk than female or older SLE patients, which suggested that SLE is associated with the risk of osteoporotic fracture. One possible explanation is that SLE patients have a higher rate of premature menopause and the use of glucocorticoid at a younger age.

The findings of the present study provide the first evidence of an independent association between SLE and the risk of osteoporotic fracture using a larger, nationwide population-based cohort from Korea. Consequently, we believe that our findings could be used as a fundamental data for treatment and future prevention of osteoporotic fracture in Korean SLE patients by understanding of risk factors for osteoporotic fracture. However, there are several limitations to this study. First, our data did not identify the use of drugs such as glucocorticoids, anticonvulsants, hydroxychloroquine, calcineurin inhibitors, vitamin D supplements, and bisphosphonates, which could affect the risk of osteoporotic fracture. Second, we did not evaluate the association of osteoporotic fracture risk with SLE patients according to other sites, such as the vertebrae, hip, ankle, or wrist. Future studies are required to determine the influence of drug use and fracture site on the risk of osteoporotic fractures.

In this large population-based cohort study, we found that there was an approximately 3-fold increased risk of osteoporotic fracture in SLE patients, when compared to age- and sex-matched non-SLE controls. Male or middle-aged SLE patients had a relatively higher fracture risk among SLE patients. Therefore, strategies to prevent osteoporotic fracture, including the treatment of osteoporosis in SLE patients, should be examined in the future, especially in both male and younger patients.

1. We found a 2.96-fold increased risk of osteoporotic fracture in systemic lupus erythematosus (SLE) patients compared to age- and sex-matched non-SLE controls.

2. Male or middle-aged SLE patients had a relatively higher fracture risk among patients with SLE.